Who are Influsplit® Tetra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quadrivalent VLP Influenza Vaccine, Comirnaty Original/Omicron BA.1, mRNA-1273 vaccine, BNT162b2 Bivalent (WT/OMI BA.1), mRNA-1273, The Pfizer mRNA-based BNT162b2 vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/influsplit-tetra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Influsplit® Tetra — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influsplit® Tetra (Influsplit® Tetra) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

phase 3 mRNA vaccine Influenza hemagglutinin and neuraminidase antigens Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Influsplit® Tetra (Influsplit® Tetra) — ModernaTX, Inc.. Influsplit® Tetra is a quadrivalent mRNA vaccine that encodes influenza virus surface antigens to stimulate immune responses against four strains of influenza.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Influsplit® Tetra TARGET	Influsplit® Tetra	ModernaTX, Inc.	phase 3	mRNA vaccine	Influenza hemagglutinin and neuraminidase antigens
Quadrivalent VLP Influenza Vaccine	Quadrivalent VLP Influenza Vaccine	Medicago	phase 3	Quadrivalent influenza vaccine	Influenza hemagglutinin and neuraminidase antigens
Comirnaty Original/Omicron BA.1	Comirnaty Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
mRNA-1273 vaccine	mRNA-1273 vaccine	University Health Network, Toronto	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
mRNA-1273	mRNA-1273	Assistance Publique - Hôpitaux de Paris	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
The Pfizer mRNA-based BNT162b2 vaccine	The Pfizer mRNA-based BNT162b2 vaccine	dafna yahav	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Influsplit® Tetra — Competitive Intelligence Brief. https://druglandscape.com/ci/influsplit-tetra. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing